Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.72 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244510 | 1.00 | FFAR1 (0.72) | FFAR1PPARDPPARAMRGPRX4PPARG | |
| SCHEMBL12348753 | 0.90 | FFAR1 (0.61) | FFAR1PPARDPPARAMRGPRX4PPARG | |
| SCHEMBL16326316 | 0.89 | FFAR1 (0.75) | FFAR1PPARDPPARAMRGPRX4PPARG | |
| SCHEMBL3518826 | 0.84 | FFAR1 (1.00) | FFAR1PPARDPPARAMRGPRX4PPARG | |
| SCHEMBL13140168 | 0.83 | FFAR1 (0.79) | FFAR1PPARDPPARAMRGPRX4PPARG | |
| SCHEMBL13550323 | 0.83 | FFAR1 (0.79) | FFAR1PPARDPPARAMRGPRX4PPARG | |
| SCHEMBL3525795 | 0.82 | FFAR1 (0.88) | FFAR1PPARDPPARAMRGPRX4PPARG | |
| SCHEMBL3524415 | 0.82 | FFAR1 (1.00) | FFAR1PPARDPPARAMRGPRX4PPARG | |
| SCHEMBL13118336 | 0.82 | FFAR1 (0.76) | FFAR1PPARDPPARAMRGPRX4PPARG | |
| SCHEMBL6104695 | 0.81 | FFAR1 (1.00) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | FFAR1 25/4885PPARD 36/4885PPARA 56/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | FFAR1 25/4885PPARD 36/4885PPARA 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.